Marker Therapeutics (MRKR) Profit After Tax (2010 - 2026)

Marker Therapeutics (MRKR) has reported Profit After Tax for 17 consecutive years, with -$3.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 28.49% year-over-year to -$3.2 million; the TTM figure through Mar 2026 stood at -$10.9 million (up 14.77% YoY), while the FY2025 annual figure was -$12.2 million, down 13.35% from the prior year.
• Profit After Tax eased to -$3.2 million in Q1 2026 per MRKR's latest filing, from -$1.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$1.7 million in Q4 2025 and bottomed at -$9.9 million in Q1 2022.
• Historically, Profit After Tax has averaged -$4.5 million across 5 years, with a median of -$3.9 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax jumped 60.5% — and 2023, when it slumped 123.32%.
• Marker Therapeutics' Profit After Tax stood at -$3.9 million in 2022, then sank by 123.32% to -$8.6 million in 2023, then jumped by 55.44% to -$3.8 million in 2024, then jumped by 55.62% to -$1.7 million in 2025, then sank by 86.66% to -$3.2 million in 2026.
• Business Quant data shows MRKR's Profit After Tax at -$3.2 million in Q1 2026, -$1.7 million in Q4 2025, and -$2.0 million in Q3 2025.